Circulogene Unveils Innovative OncoGenDx Tissue Assay
Circulogene has revolutionized the field of precision oncology with the launch of its groundbreaking assay, OncoGenDx. This comprehensive genomic profiling (CGP) test is designed to provide essential insights into a variety of solid tumors. By broadening its testing capabilities, Circulogene aims to deliver advanced solutions that empower clinicians in making informed treatment choices.
Transforming Diagnostic Approaches in Oncology
Aligned with Circulogene's vision, OncoGenDx enhances the existing offerings, which include OncoGenLDx—the only plasma-based test that delivers PD-L1 expression results. Furthermore, the LungLifeAI solution aids in the risk assessment of incidental lung nodules, bringing a thorough understanding into a clinician's decision-making process. The launch of OncoGenDx underlines the company's dedication to advancing solid tumor analysis through innovative and practical testing methodologies.
Streamlined Testing for Clinicians
The OncoGenDx assay has been meticulously designed for simplicity and speed. Clinicians can submit orders directly to Circulogene, with the added convenience of pathology retrieval managed by the Client Services team. Patients can expect results delivered in a combined report format, typically within 10–14 days. This quick turnaround fosters timely clinical decision-making, ultimately benefiting patient outcomes.
Robust Genomic Analysis Features
OncoGenDx offers significant technological advancements by utilizing next-generation sequencing (NGS) techniques. The assay provides a molecular analysis of formalin-fixed paraffin-embedded (FFPE) tumor tissues across varying types of solid tumors. With the ability to evaluate 335 DNA genes and 72 RNA genes, it can identify key genomic alterations such as single nucleotide variants (SNVs), insertions/deletions (Indels), copy number variations (CNVs), and structural variants (SVs). Moreover, it identifies actionable fusions, making it a critical tool for enhancing cancer treatment strategies.
Supporting Oncology Decision-Making
One of the most notable aspects of the OncoGenDx assay is its reporting of complex genomic signatures. These include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD). These factors are invaluable for guiding both targeted therapies and immunotherapies, paving the way for personalized patient care. Additionally, the option for PD-L1 IHC (22C3 clone) testing is available, further augmenting the assay's capabilities.
About Circulogene and Its Vision
Circulogene stands at the forefront of precision oncology and strives to deliver molecular diagnostics that are practical and closely aligned with clinical workflows. The company’s headquarters in Pensacola serves as a hub for innovation, yielding a product lineup that includes OncoGenLDx and LungLifeAI, ensuring a comprehensive diagnostic toolset for clinicians.
Circulogene remains committed to evolving its portfolio to meet the dynamic needs of healthcare providers. The introduction of the OncoGenDx assay marks a new chapter in the company’s mission to bridge the gap between advanced genomic science and everyday clinical practice.
Frequently Asked Questions
What is OncoGenDx?
OncoGenDx is a comprehensive genomic profiling assay developed by Circulogene for analyzing solid tumors.
How does OncoGenDx benefit clinicians?
This assay provides valuable molecular data that aids clinicians in making timely and informed treatment decisions.
What types of genomic alterations can OncoGenDx identify?
It identifies single nucleotide variants (SNVs), insertions/deletions (Indels), and other significant structural variations.
What are complex genomic signatures reported by OncoGenDx?
Complex signatures include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD).
Where is Circulogene located?
Circulogene is based in Pensacola, Florida, where it develops innovative oncology solutions.
